1 |
CFDA, 2012. CFDA releases 2011 Annual Report on National Adverse Drug Reaction Monitoring. [accessed November 2013] Available from: http://www.ccpie.org/news/download
|
2 |
PMDA. 2013. Profile of Services 2012-2013. [accessed November 2013] Available from: http://www.pmda.go.jp/english/about/index.html
|
3 |
PMDA. The Pharmaceuticals and Medical Devices Agency Annual Report FY 2011. [accessed November 2013] Available from: http://www.pmda.go.jp/english/about/annual.html
|
4 |
PMDA. The Pharmaceuticals and Medical Devices Agency Annual Report FY 2005. [accessed November 2013] Available from: http://www.pmda.go.jp/english/about/annual.html
|
5 |
최돈웅, 최미섭, 고아라. 우리나라의 의약품 안전관리 현황. 대한의사협회지 2012;55:827-34.
|
6 |
한국식품안전정보원 [accessed November 2013] Available from: http://www.foodinfo.or.kr
|
7 |
대한한의사협회 [accessed November 2013] Available from: http://www.akom.org/report
|
8 |
한국의약품안전관리원. 의약품 안전성정보 보고동향 4호. 2013.
|
9 |
Sato A, Toyoshima M, Kondo A, Ohta K, Sato H, Ohsumi A. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:391-5.
|
10 |
Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. NEJM 2000;343:1686-92.
|
11 |
이태호, 형례창, 양창섭, 외. 마황복용 후 사상 체질별 이상반응에 관한 임상연구: 무작위배정 이중맹검시험. 대한한방내과학회지 2009;30:144-52.
|
12 |
30. 황우석, 주창엽, 이재성, 외. 기관지천식 환자에 대한 소청룡탕의 부작용에 대한 평가. 대한한방내과학회 추계학술대회지 2002;49-55.
|
13 |
권영주, 조우근, 한창호. 1개 대학 한방병원에서 EMR을 통해 보고된 한약에 의한 약물유해반응의 현황. 대한한방내과학회지 2012;33:485-97.
|
14 |
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329:15-9.
DOI
ScienceOn
|
15 |
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prosepctive studies. JAMA 1998;279:1200-5.
DOI
ScienceOn
|
16 |
국가법령정보센터. 의약품등 안전성정보관리 규정 제2조. [accessed November 2013]. Available from: www.law.go.kr
|
17 |
Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991;84:341-4.
DOI
|
18 |
Institute Of Medicine. To Err is Human: Building a safer health system. Washington DC: National Academy Press; 1999, p. 27.
|
19 |
Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006; 26:601-8.
DOI
ScienceOn
|
20 |
박실비아, 채수미. 외국의 의약품 부작용 피해구제제도 현황과 국내 실시 방안. 한국임상약학회지 2008;18:18-27.
|
21 |
Gawert L, Hierse F, Zink A, et al. The importance of patient perspective in drug survailance systems. Z Rheumatol 2010;69:795-802
DOI
ScienceOn
|
22 |
박병주. 의약품 부작용 모니터링. 병원약사회지 1999;16:99-107.
|
23 |
강휘중, 김효동, 박호재, 외. 일본동양의학회지에 수록된 '부작용'에 관한 논문 분석 - 한약 단독 투여시의 부작용. 한국한의학연구원논문집 2011; 17:47-56.
|
24 |
이선동. 한약.생약, 한약제제 및 생약제제 부작용에 관련 보고체계 마련 및 활성화연구. 식품의약품안전청 연구보고서 2007.
|
25 |
지제근. 알기쉬운 의학용어풀이집. 제3판. 서울: 고려의학; 2009.
|
26 |
국가법령정보센터. 약사법 제2조 4항. [accessed November 2013]. Available from: www.law.go.kr
|
27 |
Shaw D. Toxicological risks of Chinese herbs. Planta Med 2010;76:2012-8.
DOI
ScienceOn
|
28 |
CFDA, 2013. CFDA releases 2012 Annual Report on National Adverse Drug Reaction Monitoring. [accessed November 2013]. Available from: http://www.ccpie.org/news/download
|
29 |
WHO-UMC. About UMC. [accessed November 2013] Available from: http://www.who-umc.org/DynPage.aspx?id=96979&mn1=7347&mn2=7469
|
30 |
Classification and monitoring safety of Herbal medicines, [accessed November 2013] Available from:http://www.who-umc.org/graphics/24727.pdf
|
31 |
Zhang L, Yan J, Liu X, et al. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: Current status and future perspective. J Ethnopharmacol 2012;140:519-25.
DOI
ScienceOn
|